Comparison of symptom burden/toxicity, neurocognitive change, and functional outcomes in pediatric brain tumor patients treated with proton VS. Photon radiotherapy

Active Project Grant Awarded Last action

Award ID
R01CA249988
Recipient
Awarding agency
Obligated
$12,296,015

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 87% complete
Originally
Funding
  • $10,889,045.00 Federal
  • $1,406,970.00 Non-federal
Place of performance
Houston, TX 77030, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Most children treated for cancer in the US will achieve long-term survival, and survivorship presents unique challenges for this growing population. Pediatric brain tumor survivors, in particular, are at risk for neurocognitive impairments, educational difficulties, social problems, and medical disabilities. Cranial radiation therapy is an essential lifesaving treatment but is associated with cognitive decline. Proton beam radiation therapy (pbrt) is one of the most promising recent advances in pediatric brain tumor treatment. The proposed medical advantage of pbrt lies in the precision of radiation delivery with proton beams, depositing maximum dose to clinical targets while minimizing radiation to surrounding tissues. By reducing dose to healthy brain tissue, pbrt may spare cognitive functioning and reduce symptom burden better than conventional photon or x-RAY irradiation (XRT) leading to greater functional independence in survivorship. Using a model-based, accelerated longitudinal cohort comparison design, we will compare symptom burden/toxicity, neurocognitive change, and functional outcomes at multiple data points from start of radiation through late survivorship in patients treated with pbrt versus XRT. The following aims are proposed: (1) to compare symptom burden and toxicity by RT type in pediatric brain tumor patients and survivors, (2) to compare change in neurocognitive outcomes over time by RT type, (3) to compare functional outcomes in early and late survivorship by RT type, and (4) to examine relations among symptom burden/toxicity, neurocognitive function, and functional outcomes as a function of RT type. This proposal is consistent with NCI's objective to "reduce the long-term adverse effects of cancer and its treatment" in children and to "improve the quality of life for cancer patients, survivors, and their families." neurocognitive late effects lead to significant educational, social, and occupational limitations for many survivors, greatly affecting their quality of life and functional independence long-term. Research is needed to determine which treatments are best able to limit the suffering associated with symptom burden and post- treatment neurocognitive decline. Our results will have clinical value, providing a timely comparison of symptoms, neurocognitive changes, and functional outcomes between pbrt and XRT groups that will guide clinicians and families on the range of outcomes to expect after pbrt.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $237,541 $0
Amendment $212,666 $0
Amendment $19,727 $0
Amendment $922,431 $0
Amendment $1,295,120 $0
Amendment $115,672 $0
Amendment $115,672 $0
Amendment $1,278,132 $0
Amendment $1,278,132 $0
Amendment $37,978 $0
Amendment $37,978 $0
Amendment $37,978 $0
Amendment $1,243,039 $0
Amendment $1,243,039 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,406,970 $0
Original award $1,406,970 $1,406,970
Show all 21

Subawards

Subrecipient Amount Awarded
Children's Hospital Agreement: $104,642 Amd 1: $0 Amd 2: $90,448 Amd 3: $99,362 Amd 4: $99,453 Under the direction of Pamela Hinds, Children's National will be responsible for… $393,905
The Univeristy Of Texas M.d. Anderson Cancer Center Agreement: $44,869 Amd 1:$0 Amd 2: $33,544 Amd 3: $32,765 Amd 4: $0 Amd 5: $32,406 Patients enrolled at the Texas Children's Cancer Center will received… $143,584
The Hospital For Sick Children Agreement: $228,357.36 Amd 1: ... Amd 2: $221,355 (P700000136) Amd 3: $229,892 Amd 4: $0 Amd5: $220,153(P700000136) Amd 6: $237,541(P700001619) Under the… $1,137,298
Murdoch Children's Research Institute Agreement: $202,452 Amd 1: $200,187 (P700000203) Amd 2: $204,365 Amd 3: $0 (P700000203) Amd 4: $212,666(P700001633) The Royal Children's Hospital (RCH) -… $819,670
University Health Network Agreement: $21,244 Amd 1: $20,417 Amd 2: $20,073 Amd 3: $19,060 Amd 4: $19,727 All XRT participants will be patients of and enrolled through SickKids, but the… $100,521

Quick answers

Who received award R01CA249988?

R01CA249988 was awarded to Baylor College Of Medicine by National Cancer Institute (National Institutes of Health) on March 1, 2021.

How much is award R01CA249988 worth?

$12,296,015 has been obligated on R01CA249988: $10,889,045 in federal funding and $1,406,970 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login